Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 6731

BillFederalHouseIn Committee
Securing America’s Pharmaceutical Supply Chain Act
About This Bill
Committee
Latest Action · May 5, 2020
Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress
116th (2019–2021)
Introduced
May 5, 2020
Cosponsors (3)
1D 2R
View PDF ↗

Summary

Highlight any text to annotate
Securing America's Pharmaceutical Supply Chain Act This bill allows an executive agency to purchase a drug approved or licensed by the Food and Drug Administration only if the drug is over 50% sourced, manufactured, and assembled in the United States. This requirement may be waived (1) if the drug is not available in sufficient quantity or quality as over 50% sourced, manufactured, and assembled in the United States; or (2) during an emergency. The U.S. Trade Representative (USTR) shall modify U.S. product coverage under all free trade agreements and the World Trade Organization Agreement on Government Procurement to exclude coverage of essential medicines and medical countermeasures. Subsequent to such modifications, the USTR shall make any necessary corresponding modifications of existing waivers and notify the Office of Management and Budget.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.